GlassScriptPhysician profile
Aayush Shah
NPI 1730762949
$1,248.53
in general payments reported to CMS, 2019-2025
12 companies · $976 in 2025
The $976 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $21.65 · 2023: $34.32 · 2024: $216 · 2025: $976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,226.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $309.79 | 2025 | Sapien 3 Ultra Resilia |
| Amgen INC. | $206.26 | 2024-2025 | Repatha, Repatha |
| Cardiva Medical, INC. | $145.84 | 2025 | Cardiva Vascade 5f Vcs, Cardiva Vascade 6/7f Vcs, Cardiva Vascade Mvp Vvcs 6-12f |
| Bridgebio Pharma, INC. | $136.83 | 2025 | Attruby |
| Abiomed | $115.24 | 2024-2025 | Impella |
| Boston Scientific Corporation | $114.39 | 2025 | Seismiq Lithotrip _ic |
| Actelion Pharmaceuticals US, INC. | $61.32 | 2025 | Uptravi, Opsumit |
| Medtronic, INC. | $50.54 | 2025 | Cobalt Dr Mri Surescan |
| Janssen Pharmaceuticals, INC | $33.81 | 2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $18.54 | 2024 | Farxiga |
| Merck Sharp & Dohme LLC | $18.08 | 2023 | Recarbrio, Dificid, Zerbaxa |
| Alexion Pharmaceuticals, INC. | $16.24 | 2023 | Soliris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aayush Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.